Regeneron Pharmaceuticals Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for REGN, updated each market day.
REGN AI Sentiment
AI sees no strong directional signal for Regeneron Pharmaceuticals Inc stock over the next 10 market days.
Prediction date: May 18, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Sector
Exchange
Market Cap
$74,736,600,741
Cap Tier
Employees
15,410
Headquarters
TARRYTOWN, NY
Listed Since
April 2, 1991
Website
REGN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
REGN Volatility
Regeneron Pharmaceuticals Inc has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
